Meagan C Fitzpatrick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4908210/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA. The Lancet Regional Health Americas, 2022, 6, 100147.	1.5	16
2	Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition Is Associated With Individual Exposure but Not Community-Level Transmission. Journal of Infectious Diseases, 2022, 226, 225-235.	1.9	4
3	Estimating COVID-19 Infections, Hospitalizations, and Deaths Following the US Vaccination Campaigns During the Pandemic. JAMA Network Open, 2022, 5, e2142725.	2.8	38
4	Quarantine and testing strategies to ameliorate transmission due to travel during the COVID-19 pandemic: a modelling study. Lancet Regional Health - Europe, The, 2022, 14, 100304.	3.0	20
5	Cost-effective proactive testing strategies during COVID-19 mass vaccination: A modelling study. The Lancet Regional Health Americas, 2022, 8, 100182.	1.5	10
6	Model-Estimated Association Between Simulated US Elementary School–Related SARS-CoV-2 Transmission, Mitigation Interventions, and Vaccine Coverage Across Local Incidence Levels. JAMA Network Open, 2022, 5, e2147827.	2.8	12
7	Estimated Transmission Outcomes and Costs of SARS-CoV-2 Diagnostic Testing, Screening, and Surveillance Strategies Among a Simulated Population of Primary School Students. JAMA Pediatrics, 2022, 176, 679.	3.3	11
8	Exacerbation of COVID-19 mortality by the fragmented United States healthcare system: A retrospective observational study. The Lancet Regional Health Americas, 2022, 12, 100264.	1.5	7
9	Universal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	22
10	Buyer beware: inflated claims of sensitivity for rapid COVID-19 tests. Lancet, The, 2021, 397, 24-25.	6.3	34
11	The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clinical Infectious Diseases, 2021, 73, 2257-2264.	2.9	376
12	Optimal COVID-19 quarantine and testing strategies. Nature Communications, 2021, 12, 356.	5.8	164
13	Optimizing age-specific vaccination. Science, 2021, 371, 890-891.	6.0	38
14	Racial disparities in COVID-19 mortality across Michigan, United States. EClinicalMedicine, 2021, 33, 100761.	3.2	26
15	Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. Lancet Public Health, The, 2021, 6, e184-e191.	4.7	106
16	Simulated Identification of Silent COVID-19 Infections Among Children and Estimated Future Infection Rates With Vaccination. JAMA Network Open, 2021, 4, e217097.	2.8	22
17	The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region. Vaccine, 2021, 39, 2165-2176.	1.7	11
18	Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLoS Biology, 2021, 19, e3001211.	2.6	111

MEAGAN C FITZPATRICK

#	Article	IF	CITATIONS
19	Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants. EClinicalMedicine, 2021, 35, 100865.	3.2	100
20	Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions. Vaccine, 2021, 39, 5037-5045.	1.7	17
21	Influenza vaccination should have no border: cost-effectiveness of cross-border subsidy. BMC Public Health, 2021, 21, 1543.	1.2	3
22	Passing the Test: A Model-Based Analysis of Safe School-Reopening Strategies. Annals of Internal Medicine, 2021, 174, 1090-1100.	2.0	26
23	Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	345
24	Asymptomatic Infection and Transmission of Pertussis in Households: A Systematic Review. Clinical Infectious Diseases, 2020, 70, 152-161.	2.9	18
25	The imperative for universal healthcare to curtail the COVID-19 outbreak in the USA. EClinicalMedicine, 2020, 23, 100380.	3.2	15
26	Prosocial polio vaccination in Israel. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13138-13144.	3.3	16
27	The effect of Medicare for All on rural hospitals – Authors' reply. Lancet, The, 2020, 396, 1392-1393.	6.3	1
28	The case for replacing live oral polio vaccine with inactivated vaccine in the Americas. Lancet, The, 2020, 395, 1163-1166.	6.3	17
29	Cost-effectiveness of transitional US plans for universal health care. Lancet, The, 2020, 395, 1692-1693.	6.3	3
30	The implications of silent transmission for the control of COVID-19 outbreaks. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17513-17515.	3.3	419
31	Improving the prognosis of health care in the USA. Lancet, The, 2020, 395, 524-533.	6.3	63
32	Projecting the demand for ventilators at the peak of the COVID-19 outbreak in the USA. Lancet Infectious Diseases, The, 2020, 20, 1123-1125.	4.6	53
33	Projecting hospital utilization during the COVID-19 outbreaks in the United States. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9122-9126.	3.3	441
34	85. The Impact of Carbapenem-Sparing Interventions on the Evolution of Resistance in Pseudomonas aeruginosa in the USA. Open Forum Infectious Diseases, 2020, 7, S59-S60.	0.4	0
35	Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure. PLoS Neglected Tropical Diseases, 2019, 13, e0007482.	1.3	23
36	Modelling microbial infection to address global health challenges. Nature Microbiology, 2019, 4, 1612-1619.	5.9	34

MEAGAN C FITZPATRICK

#	Article	IF	CITATIONS
37	Impact of One-Health framework on vaccination cost-effectiveness: A case study of rabies in Ethiopia. One Health, 2019, 8, 100103.	1.5	7
38	The Impact of Influenza Vaccine: It's the Size of the Glass. Clinical Infectious Diseases, 2019, 69, 1854-1855.	2.9	2
39	Metrics and benchmarks for HIV transition – Authors' reply. Lancet HIV,the, 2019, 6, e150.	2.1	Ο
40	Ebola vaccination in the Democratic Republic of the Congo. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10178-10183.	3.3	38
41	Future epidemiological and economic impacts of universal influenza vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20786-20792.	3.3	26
42	Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Coadministered With Measles, Yellow Fever, and Meningitis A Vaccines in 9-Month-Old Malian Infants. Journal of Infectious Diseases, 2018, 218, 606-613.	1.9	23
43	Optimizing the impact of low-efficacy influenza vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5151-5156.	3.3	48
44	California Universal Health Care Bill: An Economic Stimulus and Life-saving Proposal. Obstetrical and Gynecological Survey, 2018, 73, 193-194.	0.2	0
45	Defining control of HIV epidemics. Lancet HIV,the, 2018, 5, e667-e670.	2.1	44
46	The Challenge of Vanquishing HIV for the Next Generation—Facing the Future. JAMA Pediatrics, 2018, 172, 609.	3.3	1
47	Evaluating Vaccination Strategies for Zika Virus in the Americas. Annals of Internal Medicine, 2018, 168, 621-630.	2.0	11
48	Fund global health: Save lives and money. Science, 2017, 356, 1018-1019.	6.0	1
49	California Universal Health Care Bill: an economic stimulus and life-saving proposal. Lancet, The, 2017, 390, 2012-2014.	6.3	1
50	Saving lives efficiently across sectors: the need for a Congressional cost-effectiveness committee. Lancet, The, 2017, 390, 2410-2412.	6.3	8
51	HIV criminalization exacerbates subpar diagnosis and treatment across the United States. Aids, 2017, 31, 2437-2439.	1.0	9
52	A Cost-Effectiveness Tool for Informing Policies on Zika Virus Control. PLoS Neglected Tropical Diseases, 2016, 10, e0004743.	1.3	56
53	One Health approach to cost-effective rabies control in India. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14574-14581.	3.3	63
54	Epidemiological and Economic Effects of Priming With the Whole-Cell <i>Bordetella pertussis</i> Vaccine. JAMA Pediatrics, 2016, 170, 459.	3.3	22

MEAGAN C FITZPATRICK

#	Article	IF	CITATIONS
55	Cost-effectiveness of next-generation vaccines: The case of pertussis. Vaccine, 2016, 34, 3405-3411.	1.7	3
56	Optimal frequency of rabies vaccination campaigns in Sub-Saharan Africa. Proceedings of the Royal Society B: Biological Sciences, 2016, 283, 20161211.	1.2	10
57	Cost-Effectiveness of Pertussis Vaccination During Pregnancy in the United States. American Journal of Epidemiology, 2016, 183, 1159-1170.	1.6	43
58	Cost-Effectiveness of Canine Vaccination to Prevent Human Rabies in Rural Tanzania. Annals of Internal Medicine, 2014, 160, 91-100.	2.0	71
59	Borrelia burgdorferi Promotes the Establishment of Babesia microti in the Northeastern United States. PLoS ONE, 2014, 9, e115494.	1.1	91
60	Potential for Rabies Control through Dog Vaccination in Wildlife-Abundant Communities of Tanzania. PLoS Neglected Tropical Diseases, 2012, 6, e1796.	1.3	46
61	Segmental Duplication Implicated in the Genesis of Inversion 2Rj of Anopheles gambiae. PLoS ONE, 2007, 2, e849.	1.1	28
62	Centromere-proximal differentiation and speciation in Anopheles gambiae. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15930-15935.	3.3	96
63	Re-Emergence of Pertussis in Israel Retains Periodicity of Pre-Vaccine Era. SSRN Electronic Journal, 0, ,	0.4	0